Genmab — December 2020
-
CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies https://www.mdpi.com/1422-0067/21/24/9531/htm
-
Regeneron is pausing new enrollment of patients with B-cell non-Hodgkin lymphomas (B-NHL)
in its trials for odronextamab, a CD20xCD3 bispecific antibody, in compliance with a U.S. Food
and Drug Administration (FDA) partial clinical hold. https://investor.regeneron.com/index.php/static-files/690eeaf2-643e-44eb-9c3f-baad97eb9703 -
Crazy - REGN experiences serious safety issues and Epco is serously considered for home administration...
-
Maybe marketing people can make use of this...
-
Genmab bevarer kursmål efter kapitalmarkedsdag
https://www.proinvestor.com/investornyt/670386/genmab-bevarer-kursmal-efter-kapitalmarkedsdag -
Dejligt med noget søgang!!...god gevinst på mine bull´s. Man skal bare lige ind i rytmen..:-D
-
Ser ud til at US har svært ved at yde assistance i dag....
-
ADS´en er næsten i grønt.
-
Så må vi se om de sætter en slutspurt ind.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind